Progetti :“A
Phase 2 Randomized, DoubleBlind, Placebo-Controlled, Multicenter
Study to Evaluate the Efficacy and Safety of AL002 in Participants
with Early Alzheimer’s Disease” (AL002-2) e “A Multicenter,
Long-Term Extension Study To Evaluate The Safety, Tolerability, And
Efficacy Of Al002 In Participants With Alzheimer’s Disease”
(AL002-LTE) per
le esigenze della Struttura Complessa di Neurologia - OCB.